Founder and Chief Executive Officer Fawad Maqbool said the quarter showed year-over-year revenue growth, expansion in the O-RAN 5G and Spectrum divisions and gross margin improvement from the second quarter. He also said the timing of large 5G deployments andManufacturingexecution had not matched the …
Management said its broader priority remains disciplined management of its assets, strengthening its financial foundation and pursuing strategic opportunities that can contribute to sustainableLong-term GrowthandShareholdervalue.
Chairman and Chief Executive Officer Mark Vorsatz said third-quarter revenue grew about 18.7%, or about USD 53 million, and that year-to-date revenue was about USD 795 million, up about 19.1%. Chief Financial Officer Neal Livingstone said last-twelve-month revenue was USD 966 million, up 19.2%, …
Adjusted EBITDA totaled USD 125.9 million with a consolidated margin of 9.5%. Underlying adjusted EBITDA grew 9%, with food and paper costs improving for the third consecutive quarter. Brazil's adjusted EBITDA grew about 10% in U.S. dollars from the prior-year quarter.
The quarter also included regulatory progress for its lead candidate, AP-SA02, which is being developed for the treatment of complicated S. aureus bacteremia. The filing states that the FDA granted Breakthrough Therapy designation to AP-SA02 on September 14, 2026, and that the company obtained …
The company incurred a net loss of USD 7,153 thousand during the nine months ended September 30, 2026, and held cash and cash equivalents of USD 4,437 thousand at September 30, 2026. The filing includes aGoing Concernsection describing losses since inception.
Total revenue for fiscal 2026 was USD 450.8 million, against USD 829.4 million in fiscal 2025. Collaboration and license revenue was USD 444.2 million and product revenue, net, was USD 6.6 million. The filing attributes the decrease to lower revenue recognition under the Sarepta …
The company operates the Accelerant Risk Exchange, a platform that houses its technology and data capabilities for specialty underwriters. The filing says Exchange Services captures theRevenueand expenses associated with that platform.
Collaboration revenue from a related party was USD 3.0 million for the three months ended September 30, 2026, against USD 10.8 million a year earlier. For the nine months, it was USD 24.5 million, against USD 29.8 million. The filing states the company recognized …
Global Yorvipath revenue in the third quarter was EUR 291 million, up 103% over last year and up EUR 39 million from the second quarter. Management described Yorvipath as the first and only approved treatment for hypoparathyroidism in adults, now available commercially or through …